Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label, multicenter phase Ib/II study of HRS2398 tablets combined with adebrelimab in advanced solid tumors
CTR20241965Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of HRS2398, adebrelimab in Nonhematologic neoplasms, sponsored by Hengrui Therapeutics. Started Jun 2024; status: active.
02
Drugs
HRS2398adebrelimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on CTR20241965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241965.